ArticleOncology and therapy2025
Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study.
Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology of oncologic emergency in Ethiopia: a systematic review and meta-analysis.BMC emergency medicine · 2025Pooled it
- Predictors of Hospitalization due to Febrile Neutropenia in Cancer Patients Receiving Chemotherapy.Cancer medicine · 2026Observational
- Descriptive analysis of frequency and antimicrobial susceptibility of pathogens isolated from acute leukemia patients with febrile neutropenia over a four-year period at a tertiary hospital.BMC infectious diseases · 2026Article
- Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient Populations.Antibiotics (Basel, Switzerland) · 2026Article
- Development and clinical validation of a nursing risk prediction model for chemotherapy-induced febrile neutropenia in patients with cancer.Frontiers in cell and developmental biology · 2026Article
- Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFebrile neutropenia (FN) is a major cause of dose-limiting complications in cancer treatment that predisposes patients to serious infections. Despite advancements in therapies, including empirical and definitive antibiotics, FN remains a major morbidity and mortality issue among patients with cancer undergoing cancer treatment. Little is known about the 30-day all-cause mortality rates from FN in Ethiopia, particularly in the Northwest Ethiopia oncology centers.
methodsThis retrospective cross-sectional study was conducted via chart review without direct patient contact at two Northwest Ethiopia oncology centers. Adult patients diagnosed with cancer who developed FN and were treated at the two oncology centers between July 2017 and July 2021 were included in the study. Multivariable logistic regression was used to identify factors associated with 30-day all-cause mortality, with statistical significance determined at P < 0.05 and a 95% confidence interval (CI).
resultsA total of 405 patients with FN were included in the final analysis. The overall 30-day all-cause mortality was 20.7%. Age > 60 years [adjusted odds ratio (AOR) = 3.1, 95% CI (1.6-5.9), P = 0.009], low Multinational Association for Supportive Care in Cancer (MASCC) score [AOR = 4.8, 95% CI (2.5-9.1), P = 0.0001], hypoalbuminemia [AOR = 2.8, 95% CI (1.4-5.8), P = 0.026], lymphopenia [AOR = 4.9, 95% CI (2.9-6.5), P = 0.001], and elevated gamma-glutamyl transferase (GGT) [AOR = 3.5, 95% CI (1.5-4.7), P = 0.009] were significantly associated with 30-day all-cause mortality.
conclusionThe 30-day all-cause mortality rate was high among patients with FN. Old age, low MASCC score, hypoalbuminemia, lymphopenia, and elevated GGT levels were found to be significantly associated with 30-day all-cause mortality. Healthcare providers should consider these factors in order to manage and mitigate the risks associated with the 30-day all-cause mortality. Further prospective studies are warranted to confirm our results and identify therapeutic strategies that can improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.